CV Layoffs Q4

Discussion in 'Amgen' started by anonymous, Aug 19, 2016 at 7:10 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Your the know it all idiot!
     

  2. anonymous

    anonymous Guest

    You are still fired! LOSER!
     
  3. anonymous

    anonymous Guest

    If the trials don't show at least a 15% improvement in outcomes there will be no uptake from managed care. Zetia had a 6% improvement in outcomes and weren't allowed to even put it in pi because FDA felt it was insignificant. Now Repatha has better ldl lowering but it is getting many patients to single digit levels. That cannot be good. We are born with an ldl around 40. How can going way below that number be healthy? Scary shit! I have a feeling there is only going to be about a 10% benefit, falling way short of expectations. Hope I'm wrong.
     
  4. anonymous

    anonymous Guest

     
  5. anonymous

    anonymous Guest

    Whaaaaaa-touch a nerve. You must have been fired. Got u!
     
  6. anonymous

    anonymous Guest

    If you aren't fired you will be in less than a year unless you are part of the residual 40%. Those who stay will be under even greater scrutiny. Bad situation all around.
     
  7. anonymous

    anonymous Guest

    The Amgen CV division is over, it was a complete failure, Repatha is a great product for a much smaller population than was initially anticipated and corlanor has also been a complete disaster......

    the entire CV division is not only a dog but it's a dog with fleas
     
  8. anonymous

    anonymous Guest

    Repatha would be best spun out to a small specialty cardiology company with a small but nimble sales force and reduced revenue expectations.
     
  9. anonymous

    anonymous Guest

    Small but nimble - the Amgen used to be
     
  10. anonymous

    anonymous Guest

    We have a solid CV pipeline which includes another heart failure drug. Corlanor and Entresto are showing us how successful and easy heart failure drug launches are
     
  11. anonymous

    anonymous Guest

    Entresto shows signs of a turnaround. Corlanor is a lost cause.
     
  12. anonymous

    anonymous Guest

    Yes, great strategy focusing on drugs that are majority Med D. Our Repatha account managers have great relationships with those plans, especially United and Humana.
     
  13. anonymous

    anonymous Guest

    Is Amgen still marketing Corlanor? A year later and 95% of docs still haven't prescribed and never will.
     
  14. anonymous

    anonymous Guest


    it was the beginning of the end of our CV franchise
     
  15. anonymous

    anonymous Guest

    end is near
     
  16. anonymous

    anonymous Guest


    When will it start
     
  17. anonymous

    anonymous Guest

    What's the latest scoop? Are we all screwed?
     
  18. anonymous

    anonymous Guest

    When the CV outcomes are less than what Amgen had hoped. There will still be reps, but the question is how many and whether you will be the one axed. Can't say at this point yet.
     
  19. anonymous

    anonymous Guest

    Who in Amgen's elite executive management team will be held accountable for this CV clusterf***? Billions of dollars wasted on in-licensed products strategy and Repatha development and commercialization that has failed to deliver the presented results. Pounding a square peg into a round hole strategy from the start. Will it be... Suzanne? Sean? Vanessa? Tony? Bob?
     
  20. anonymous

    anonymous Guest


    Yes, at least 2 of them for now. Also salary cuts across the board.